The Transparency Task Force’s Fifth Question
We want to know how the FDA could provide information to the public to better explain the agency's work and its decisions. The fifth question is:
As FDA becomes more transparent, what information should remain confidential in order to promote key internal and external policy goals, such as preserving patient privacy, and how, in these cases, should FDA explain the importance of confidentiality?
Thank you and we look forward to your input and participation.
FDA Transparency Task Force